Suppr超能文献

健康和患病人类肾脏中膜攻击复合物的沉积。

Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

机构信息

Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands.

出版信息

Front Immunol. 2021 Feb 11;11:599974. doi: 10.3389/fimmu.2020.599974. eCollection 2020.

Abstract

The membrane attack complex-also known as C5b-9-is the end-product of the classical, lectin, and alternative complement pathways. It is thought to play an important role in the pathogenesis of various kidney diseases by causing cellular injury and tissue inflammation, resulting in sclerosis and fibrosis. These deleterious effects are, consequently, targeted in the development of novel therapies that inhibit the formation of C5b-9, such as eculizumab. To clarify how C5b-9 contributes to kidney disease and to predict which patients benefit from such therapy, knowledge on deposition of C5b-9 in the kidney is essential. Because immunohistochemical staining of C5b-9 has not been routinely conducted and never been compared across studies, we provide a review of studies on deposition of C5b-9 in healthy and diseased human kidneys. We describe techniques to stain deposits and compare the occurrence of deposits in healthy kidneys and in a wide spectrum of kidney diseases, including hypertensive nephropathy, diabetic nephropathy, membranous nephropathy, IgA nephropathy, lupus nephritis, C3 glomerulopathy, and thrombotic microangiopathies such as the atypical hemolytic uremic syndrome, vasculitis, interstitial nephritis, acute tubular necrosis, kidney tumors, and rejection of kidney transplants. We summarize how these deposits are related with other histological lesions and clinical characteristics. We evaluate the prognostic relevance of these deposits in the light of possible treatment with complement inhibitors.

摘要

膜攻击复合物-也称为 C5b-9-是经典途径、凝集素途径和替代途径的终产物。它被认为通过引起细胞损伤和组织炎症,导致硬化和纤维化,在各种肾脏疾病的发病机制中发挥重要作用。因此,在开发抑制 C5b-9 形成的新型疗法(如依库珠单抗)时,针对这些有害作用。为了阐明 C5b-9 如何导致肾脏疾病,并预测哪些患者受益于这种治疗,了解 C5b-9 在肾脏中的沉积至关重要。由于 C5b-9 的免疫组织化学染色未常规进行,并且从未在研究之间进行比较,因此我们提供了对健康和患病人类肾脏中 C5b-9 沉积的研究综述。我们描述了染色沉积物的技术,并比较了健康肾脏和广泛的肾脏疾病(包括高血压性肾病、糖尿病肾病、膜性肾病、IgA 肾病、狼疮肾炎、C3 肾小球病和血栓性微血管病,如非典型溶血性尿毒症综合征、血管炎、间质性肾炎、急性肾小管坏死、肾肿瘤和肾移植排斥)中沉积物的发生。我们总结了这些沉积物与其他组织学病变和临床特征的关系。我们根据可能使用补体抑制剂治疗的情况,评估了这些沉积物的预后相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/5c997ba3f2cf/fimmu-11-599974-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验